Indeed, the blockade of the PD-1/PD-L1 pathway is a highly effective therapeutic approach for the majority of patients with classical HL, characterized by an overexpression of PD-L1 in tumor cells due to the alteration in chromosome 9p24.1 [197,198]. The gene discussed is CD274; the disease is Hodgkins lymphoma.